Advertisement

Topics

Companies Related to "ObsEva Starts Phase Clinical Program Nolasiban" [Most Relevant Company Matches] RSS

06:49 EST 17th December 2018 | BioPortfolio

Here are the most relevant search results for "ObsEva Starts Phase Clinical Program Nolasiban" found in our extensive corporate database of over 50,000 company records.

Showing "ObsEva Starts Phase Clinical Program Nolasiban" Companies 1–25 of 6,500+

Relevant

NightstaRx Limited

Nightstar is a leading retinal gene therapy company focused on developing and commercializing novel, potentially curative one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness, and for which there are no other treatment options. Nightstar’s lead program, NSR-REP1, is being developed ...


Pharmacopeia Drug Discovery

Pharmacopeia is committed to discovering and developing novel therapeutics to address significant medical needs. The Company has a broad portfolio advancing toward clinical validation, both independently and with partners. Pharmacopeia's most advanced internal program is a dual-acting angiotensin and endothelin receptor antagonist (DARA) for hypertension and diabetic kidney disease for which Phase...

AVROBIO, Inc.

AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical-stage company developing disruptive therapies that have the potential to transform patients’ lives with a single dose. The Company is focused on the development of its Phase 1 program in Fabry disease and pre-Phase 1/2 program in Gaucher disease, while actively building a pipeli...


Worldwide Clinical Trials

Accelerate Your Development Program with Pinpoint Therapeutic Focus and Complete Spectrum of Services Worldwide Clinical Trials is a global CRO that provides full-service drug development services to the pharmaceutical and biotechnology industries.   As one of the most innovative and scientifically-driven contract research organizations, we offer exceptionally strong clinical trial m...

EnVivo Pharmaceuticals, Inc.

EnVivo Pharmaceuticals, Inc. and its subsidiaries (“EnVivo Pharmaceuticals” or “EnVivo”) are dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system (CNS). EnVivo Pharmaceuticals, Inc. is a biotech company located in Watertown, Mass. The company’s focus is on building an ...

Progen Pharmaceuticals

Progen Pharmaceuticals Limited (NASDAQ:PGLA; ASX: PGL) is a globally focused biotechnology company committed to improving patient outcomes through discovery and development of small molecule-based cancer therapeutics. The company has an intimate understanding of the role of heparan sulfate, a complex sugar, in cancer disease processes and have developed a small-molecule drug development program i...

Dynavax Technologies

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative therapeutic products to treat and prevent infectious diseases, allergies, and cancer. Our versatile, proprietary approaches alter specific immune responses by activating a unique receptor called Toll-Like Receptor 9 (TLR9) found on certain immune system cells. To target TLR9, we are using immunostimulat...

Quantum Clinical Research

Global Clinical Trial/Project Management Therapeutic Specialization Phase I Clinical Trial Mgmt Capabilities Phase II-III Capabilities Phase IIIb –IV Capabilities Post marketing Surveillance Treatment IND & Compassionate Use Regulatory Operations & QA Capabilities Worldwide Drug Safety Clinical Trial Monitoring CRA/Monitor Training Select Biometrics Capabilities

Pharma Biresearch

Pharma Bio-Research is an independent CRO, located in The Netherlands. We offer the full range of services for phase I/IIA clinical research, bioanalysis and biometrics with the most competitive time lines, excellent quality, reliability and efficiency. Reducing timelines to a minimumComplete integration of activities (clinical research, bioanalysis and biometrics/statistics) enables efficient man...

resTORbio, Inc.

resTORbio, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio’s lead program is targeting the target of rapamycin complex 1 (TORC1) pathway to treat aging-related diseases and conditions with an initial focus on conditions caus...

Oncolytics Biotech Inc.

Oncolytics Biotech Inc. was formed in 1998 to develop its proprietary product, REOLYSIN®, as a potential therapeutic for a wide variety of human cancers. Oncolytics has completed five clinical trials with REOLYSIN® in Canada and the U.K. and is currently conducting four Phase I or Phase I/II REOLYSIN® trials in the U.K. and the U.S. The company also has permission to commence a Phase II combina...

AnorMED Inc.

AnorMED was founded in 1996 and listed on the TSX as “AOM” in 1999 and on the AMEX as "AOM" in 2005. To date, the Company has raised over $160 million to support its research and development programs. Over the past years AnorMED has grown to over 140 employees - the majority of which are scientists - including chemists, biochemists and biologists. Unlike many biotech companies that focus on d...

Avancia Clinical Research

Avancia Clinical Research is an independent clinical research company in South Florida.We conduct Phase II, Phase III and Phase IV Clinical Trials at our research facility in Pembroke Pines.Avancia Clinical Research provides clinical research services for the following disorders and therapeutic areas:*Dermatology*Diabetes *Diabetic Neuropathy*Family Medicine *Gastroenterology *Geriatrics *Headache...

Coronado Biosciences, Inc.

Coronado Biosciences, Inc. is a private, clinical stage company that is focused on the development of therapeutic products for the treatment of cancer. Coronado has three programs; cndo102 activated NK cells for the treatment of relapsed/refractory AML, cndo101, a 4th generation doxorubicin analogue for the treatment of women with breast cancer who have the CAP17 duplication, and C1, a pan Bcl-2 ...

Clinical Network Services (CNS)

Clinical Network Services (CNS) Pty Ltd is an Australian CRO, focused on providing full contract research organisational clinical trial services to the international healthcare community particularly during the early phase (Phase I and Phase II) clinical development of their products. CNS has established itself as Brisbane’s only headquartered Australian CRO working both nationally with dedicat...

Esperion Therapeutics Inc.

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002, Esperion's lead product candidate, is a unique, first-in-class, orally avail...

Emergent BioSolutions

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple mission—to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Our biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterroris...

FortuneRock (China) Ltd.

FortuneRock (China) Ltd., a privately held biotechnology and biopharmaceutical company registered in Beijing. Along with its 3 wholly owned subsidiaries, Tianjin SinoBiotech Ltd., SinoBiotech (Tianjin) Ltd. and Beijing Bio-Fortune Ltd., the group is focused on the discovery, development, and commercialization of novel, patent-protected gene-based recombina...

VBL Therapeutics

VBL Therapeutics is an innovative, clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer. VBL has pioneered the Lecinoxoid class of oral anti-inflammatory agents and VB-201 is the lead candidate from this program, which has entered Phase 2 clinical development in patients with psor...

Richmond Pharmacology Ltd

Our goal is to deliver full service Early Phase clinical solutions swiftly, efficiently, and to the highest clinical standard. Our integrated set-up is designed to manage your Early Phase study within the controlled environment of Phase I. We compliment this through our out-patient facilities offering flexibility through the Phases in clinical trials.“Richmond Pharmacology is the UK's only Early...

HPI Clinical Studies Program

HPI Clinical Studies Program (HPI-CSP) is a multi-specialty investigator site organization located in Kingsport and Bristol, Tennessee, an area growing in reputation for providing quality investigators and a reliable patient population.HPI-CSP presently includes more than 26 investigators, 7 coordinators, and 10 sites located within a 25-mile radius and close to a regional medical facility providi...

Tragara Pharmaceuticals

Tragara Pharmaceuticals, Inc. is a privately-held pharmaceutical company based in San Diego, Calif. The company is focused on the clinical and commercial development of proprietary medicines for the treatment of cancer and inflammation. Tragara's lead therapeutic program, Capoxigem® (apricoxib, TG01), is currently in Phase II clinical development in lung and pancreatic cancers and has completed...

Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical tri...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and psoriasis. Shape has an ongoing Phase 1b clinical study in CTCL patients and has completed a Phase 1b clinical study in psoriasis patients. The development of SHP-141 is being supp...

Akebia Therapeutics, Inc.

Akebia Therapeutics is a discovery and development company focused on anemia and vascular disorders. Akebia’s lead program, AKB-6548, an orally bioavailable HIF-prolyl hydroxylase (HIF-PH) inhibitor for patients with anemia, is in phase 2 clinical trials. AKB-6548 potentially promises to be a safer, less expensive, orally dosed pharmaceutical to stimu...


More From BioPortfolio on "ObsEva Starts Phase Clinical Program Nolasiban"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks